HIGHLIGHTS
- who: Antonios Bertsias from the School University of Crete, Voutes, Heraklion, Greece have published the research work: Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study, in the Journal: Rheumatology, Clinical Immunology and Allergy Department, Medical
- what: The authors examined the long-term flare risk and safety of reduced doses of rituximab. Lowering the cost of RA treatment and reducing long-term cumulative bDMARDs doses is the main reasons supporting this . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.